Notice of	f Intent to Prov	ide:	Albuterol		
Name of Enti	ity (Ambulance, BLSFF	, agency etc)	Telephone Num	nber	
Name of Prin	nary Contact		Primary Contact	t Phone #	
Address		,	Email Address		
City	State	Zip Code	Fax #		
	edical Director Ir	nfo	Telephone Num	ber	
Address			Email Address		
City	State	Zip Code	Fax #	_	
Authorize	d Names and Sig	natures			
CEO/COO/Chief Officer (PRINT)		Signatu	ire	Date	
Medical Director (PRINT)		Signati	ıre	 Date	

#### Additional information required

Please submit the following with this form to; EMSTAR 1058 West Church St, Elmira NY 14905

<sup>~</sup>Medical Director Verification form

<sup>~</sup>Protocol for administration of Albuterol

<sup>~</sup>Policies and procedures for your training, credentialing, and continuing education

<sup>~</sup>A defined quality assurance program

<sup>~</sup>Policies and procedures for inventory, storage, security, and proper disposal of medications and administration devices.

# **Medical Director Verification**

## Notice to Service

Please identify the physician providing Quality Assurance oversight to your individual agency. If your agency provides Defibrillation, Epi-Pen, Blood Glucometry, Albuterol or Advance Life Support (ALS), you must have specific approval from your Regional EMS Council's Medical Advisory Committee (REMAC) and oversight by a NY state licensed physician. If you change your level of care to a higher ALS level, you must provide the NYS DOH Bureau of EMS a copy of your REMAC's written approval notice.

If your service wishes to change to a lower level of care, provide written notice of the change and the level of care to be provided, and the effective date of implementation, to your REMAC with a copy to the NYS DOH Bureau of EMS.

If your agency has more than one Medical Director, please use copies of this verification and indicate which of your operations or REMAC approvals apply to the oversight provided by each physician. Please send this form to your DOH EMS Central Office for filing with your service records.

Defibrillation / PAD (BLS Level Services)	Epi Pen (Epi / Albute	Albuterol rol / Blood Glucometry per reg	Blood Glucometry gional protocol)	Naloxone
Paramedic Level of Care	Critical Care Level of Care	AEMT Level of Care	Controlled Substances (BNE License on file)	
EMS Agency (Please Type	or Print Legibly)			
Agency Name				
Agency Code Number				
Agency Type	Ambulance A	LSFR BLSFR		
Agency CEO				
Medical Director _	ame			
	ame			
	/S Physician's License Number Controlled Substance Licen	se # if Applicable: 03C –		
Ambulance/ALSFR Agency (				
,				
Medical Director Affirmati	on of Compliance			
Quality Assurance/Quality	rsician Medical Director f Improvement program fi	or the above listed EMS Age	ncy. I am responsible for oversig medical oversight on a regular	ht of the pre-hospital and on-going basis,
I am familiar with applica	ble State and Regional E ng the level of care provi	mergency Medical Advisory ( ided by this Agency.	Committee treatment protocols,	policies and applicable
state regulations concerns	ossiabt ta is uset soutifie	EMS agency and provides A	ED level care, the service has file	ed a Notice of Intent to
If the service I provide over	ersignt to is not certified brillation (DOH-4135) ar	nd a completed Collaborative	Agreement with its Regional EM	IS Council.

## **Blood Glucometry and Nebulized Albuterol**

Bureau of EMS Policy Statement			
Policy Statement #	12-01		
Date	January 10, 2012		
Subject	Blood Glucometry and Nebulized Albuterol		
Supercedes/Updates	09-13		

#### **BACKGROUND**

The New York State Emergency Medical Advisory Committee (SEMAC) has approved the use of glucometers and nebulized albuterol by Emergency Medical Technicians (EMT) who are employees/volunteers of an EMS agency (i.e. ambulance service, ALS-FR, BLS-FR). The SEMAC approval was granted with the specific condition that the EMS agency wishing to use a glucometer or nebulized albuterol, be granted approval by the Regional Emergency Medical Advisory Committee (REMAC), that each EMT from that EMS agency complete a REMAC approved training program, and that the EMS agency be granted a Limited Service Laboratory Registration (for blood glucometry only).

The purpose of this policy is to explain the approval process for EMS agencies wishing to implement a nebulized albuterol and/or blood glucometry program.

- Prehospital blood sugar evaluation is intended to assist in the recognition of hypoglycemia and improve the speed with which proper treatment is received.
- Nebulized albuterol, when administered under the Statewide BLS Adult and Pediatric Treatment Protocols has been shown to decrease respiratory distress in patients between one and sixty-five years of age who are experiencing an exacerbation of their previously diagnosed asthma.

# AUTHORIZATION FOR BLOOD GLUCOMETRY AND/OR NEBULIZED ALBUTEROL

Each REMAC will adopt protocols which will allow an EMT to obtain a blood sample, using a lancet device or equivalent, and test the blood sample in a commercially manufactured electronic glucometer. The REMAC will determine the type and level of record keeping and quality assurance required for both blood glucometry and/or nebulized albuterol. Please note that a protocol for nebulized albuterol has been approved by SEMAC and is included in the Statewide BLS Adult and Pediatric Treatment Protocols for EMT-B and AEMT.

To be authorized to use an electronic glucometer or nebulized albuterol, the EMS agency must make written request to the appropriate REMAC. The request must include, but not necessarily be limited to, the following items:

- A letter from the EMS agency physician medical director supporting the request and indicating an
  understanding of their role in the Clinical Laboratory requirements (blood glucometry only) and quality
  assurance process.
- A completed NYS Department of Health Clinical Laboratory Evaluation Program Limited Service Laboratory Registration Application (form DOH-4081) for blood testing licensure (blood glucometry only).
- Written policies and procedures for the operation of the glucometer and storage and maintenance of nebulized albuterol that are consistent with applicable Regional and State protocols. These policies and procedures shall include, but not necessarily be limited to the following:
  - didactic and psychomotor objectives for training of authorized users including who will be authorized to conduct this training;
  - documentation and attendance records of the training of authorized users;
  - a defined quality assurance program, including appropriateness review by the EMS agency physician medical director;
  - documentation of control testing process (blood glucometry only);
  - written policies and procedures for storage of the glucometer and/or nebulized albuterol, and proper disposal of sharps devices (blood glucometry only);

- notice to the EMS agency physician medical director of the use of the glucometer and/or nebulized albuterol, and;
- requirements for documentation when the glucometer and/or nebulized albuterol is used for patient care.

## LIMITED LABORATORY REGISTRATION FOR BLOOD GLUCOMETRY

New York State Public Health Law requires that any EMS agency testing blood glucose, whether by electronic glucometer or chemstrip, be required to possess a **Limited Service Laboratory Registration**. In order to obtain the Registration, EMS agencies must complete and submit the following document:

Limited Service Laboratory Registration Application (form DOH-4081)

Information and application materials are available at:

http://www.wadsworth.org/labcert/limited/index.htm

No EMS agency may engage in the testing of blood glucose without a Limited Service Laboratory Registration Certificate.

#### **NOTIFICATION**

Once the EMS agency has received written approval for blood glucometry and/or nebulized albuterol from the REMAC, the EMS agency must provide BEMS with an updated and signed Medical Director Verification Form (form DOH-4362), indicating the Limited Laboratory Registration permit number (if applicable) and authorization by the EMS agency physician medical director.

Issued and authorized by the Bureau of EMS Acting Director

Questions or comments: dohweb@health.ny.gov

Revised: October 2013